Press Releases Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-13 pm EDT			5-day change	1st Jan Change
5.030 ^USD	-3.08%		-1.18%	-63.31%

Jun. 11	Myriad Genetics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02:00 PM
Jun. 03	Myriad Genetics, Inc. Announces Early Access to the FirstGene Multiple Prenatal Screen	CI

Press Releases

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen	Jun. 03	GL
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types	Jun. 02	GL
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types	Jun. 02	AQ
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting	May. 27	GL
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences	May. 14	GL
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences	May. 14	AQ
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm	May. 08	BU
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation	May. 08	BU
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz	May. 07	BU
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology	May. 07	GL
Myriad: Q1 Earnings Snapshot	May. 06	AQ
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance	May. 06	GL
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor	Apr. 30	GL
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025	Apr. 29	GL
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting	Apr. 25	GL
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing	Apr. 21	GL
Myriad Genetics Announces Inducement Awards	Apr. 08	GL
Myriad Genetics Announces Inducement Awards	Apr. 08	AQ
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer	Apr. 07	GL
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer	Apr. 07	AQ
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools	Feb. 27	GL
Myriad: Q4 Earnings Snapshot	Feb. 24	AQ
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth	Feb. 24	GL
Myriad Genetics Announces Senior Leadership Transition	Feb. 24	GL
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio	Feb. 24	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Press Releases

Filters